Phase 1 × Carcinoma, Renal Cell × Dermatologic × Clear all
NCT04514484 2026-03-18

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

National Cancer Institute (NCI)

Phase 1 Active not recruiting
8 enrolled
NCT06910657 2026-03-02

IDOV-Immune for Advanced Solid Tumors

ViroMissile, Inc.

Phase 1 Recruiting
78 enrolled
NCT06546553 2026-02-23

A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.

Pfizer

Phase 1 Terminated
10 enrolled
NCT04485013 2026-02-18

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Tizona Therapeutics, Inc

Phase 1 Recruiting
240 enrolled
NCT05581004 2026-02-17

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Genentech, Inc.

Phase 1 Recruiting
450 enrolled
NCT01625351 2026-02-06

A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas

St. Jude Children's Research Hospital

Phase 1 Completed
23 enrolled
NCT06242470 2026-02-05

A Study of MGC026 in Participants With Advanced Solid Tumors

MacroGenics

Phase 1 Recruiting
250 enrolled
NCT02432963 2026-01-28

Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy

City of Hope Medical Center

Phase 1 Active not recruiting
11 enrolled
NCT05544929 2026-01-06

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

Novartis

Phase 1 Active not recruiting
126 enrolled
NCT03983954 2025-11-28

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

NeoTX Therapeutics Ltd.

Phase 1 Active not recruiting
120 enrolled
NCT05238883 2025-11-21

A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

HiFiBiO Therapeutics

Phase 1 Active not recruiting
72 enrolled
NCT04272034 2025-10-16

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

Incyte Corporation

Phase 1 Terminated
105 enrolled
NCT06336148 2025-10-15

A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors

Actym Therapeutics, Inc.

Phase 1 Terminated
10 enrolled
NCT04458259 2025-08-28

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

Pfizer

Phase 1 Terminated
88 enrolled
NCT03212404 2025-02-03

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

Checkpoint Therapeutics, Inc.

Phase 1 Active not recruiting
272 enrolled 1 FDA
NCT04234113 2025-01-08

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

Sotio Biotech Inc.

Phase 1 Terminated
115 enrolled
NCT06034860 2024-11-01

Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types

Molecular Templates, Inc.

Phase 1 Terminated
15 enrolled
NCT05215574 2024-10-10

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

NGM Biopharmaceuticals, Inc

Phase 1 Active not recruiting
130 enrolled
NCT03752398 2024-07-05

DUET-3

Xencor, Inc.

Phase 1 Completed
198 enrolled